SEC EDGARJUN 152 min read$RARE

Sanders Corazon (Corsee) D. sold $50K of RARE

Sanders Corazon (Corsee) D. sold 2,000 shares of Ultragenyx Pharmaceutical Inc. (RARE) at $25.05 on 2026-06-15.

Original reporting

SEC EDGAR · Sanders Corazon (Corsee) D.

Published Jun 15, 2026, 10:50 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Jun 15, 2026, 10:52 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$RARE

Neutral

medium confidence

Mentioned

$RARE

Relevance

3/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$RARENeutralLow

Why it matters

The newest fact is the director’s open-market sale of 2,000 shares at $25.05, totaling $50,100, with post-sale holdings of 21,095 shares.

Market read

This provides a fresh ownership-change datapoint but no new fundamental catalyst (no guidance, trial results, or regulatory action).

What to watch

Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs; without context on total compensation or prior sales, signal quality is limited.

Relevance 3/10Novelty 6/10Timing: SEC Form 4 filed on 2026-06-15 (transaction dated 2026-06-15)

Background

The article is an SEC Form 4 insider transaction disclosure for Ultragenyx Pharmaceutical Inc. (RARE).

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$RARENeutralMedium confidence

Context

Ultragenyx director Sanders Corazon sold 2,000 shares in an open-market transaction at $25.05 on 2026-06-15 via SEC Form 4.

Expected impact

Low likelihood of sustained price impact; any reaction is likely short-lived unless accompanied by other new catalysts.

Evidence & confidence

The filing is a director open-market sale with no 10b5-1 plan stated; however, insider sales are common and the article provides no new operational/regulatory/clinical information.

Market effects

Sector

No sector-level read-through; this is company-specific insider transaction disclosure.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

If the sale is not under a 10b5-1 plan (article says “No”), traders may interpret it as higher near-term caution, potentially pressuring the stock briefly.

Key entities

issuer
Ultragenyx Pharmaceutical Inc.
Subject of the SEC Form 4 insider transaction disclosure.
director
Sanders Corazon (Corsee) D.
Director who executed the open-market sale.

Read at source ← All news

SEP 17

$RAREHighAI 9/10

RARE Stock Jumps 13% — Extends Gains After-Hours As FDA Clears First Sanfilippo Gene Therapy

Ultragenyx Pharmaceutical Inc. (RARE) shares rose 13% during trading and 3% after-hours after the FDA approved Fayuvi, a gene therapy for Sanfilippo syndrome type A. The stock had previously hit a 52-week low. The therapy, priced at $3.95 million per patient, is Ultragenyx's second gene therapy approval. Retail sentiment on Stocktwits turned 'extremely bullish'.

stocktwits.com2 min

SEP 17

$RAREHighAI 9/10

RARE Looks 68.1% Undervalued on GF Value™ After FDA Approval Boo

Ultragenyx (RARE) received FDA approval for its gene therapy Fayuvi, the first treatment for Type A Sanfilippo syndrome. The company's P/S ratio is 2.09, below its historical median of 16.1x. GuruFocus estimates RARE is 68.1% undervalued at $14.50 per share, but notes risks due to ongoing losses and cash burn. Insiders have sold $4.0M in shares in the past year.

gurufocus.com3 min

SEP 17

$RAREHighAI 9/10

Ultragenyx Pharmaceutical Inc. (RARE): Other Events

Ultragenyx Pharmaceutical Inc. (RARE) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On September 17, 2026, Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) announced that the U.S. Food and Drug Administration (the “FDA”) granted standard full approval of FAYUVI™ (rebisufligene etisparvovec-hopf), also known as UX111, for the

SEC EDGAR 8-K1 min

SEP 17

$RAREMedAI 9/10

A fatal childhood disease gets its first FDA-approved treatment

Ultragenyx (RARE) received FDA approval for FAYUVI, the first treatment for Sanfilippo syndrome Type A. The gene therapy showed a 23.5-point improvement in cognitive scores. Commercial availability is expected in 30–60 days, with risks including liver enzyme elevations and potential malignancy. The stock rose 2.05% post-announcement.

stocktitan.net2 min

SEP 17

$RAREHighAI 9/10

Ultragenyx stock surges 10% on FDA approval for gene therapy

Ultragenyx Pharmaceutical (RARE) shares rose 10% after the FDA approved Fayuvi, a gene therapy for mucopolysaccharidosis type IIIA. This is the first FDA-authorized treatment for this rare pediatric disease. The therapy showed improved cognitive function in clinical trials but carries risks like liver enzyme increases and potential long-term tumor development.

investing.com2 min

SEP 17

$RAREHighAI 9/10

Ultragenyx gets FDA approval for rare disease gene therapy

Ultragenyx Pharmaceutical received FDA approval for Fayuvi, a gene therapy for Sanfilippo syndrome Type A. The treatment targets the enzyme deficiency causing the disease. Ultragenyx shares rose 6% on the news.

investing.com1 min

Sanders Corazon (Corsee) D. sold $50K of RARE

The 30-second read

Why it matters

Market read

What to watch

Background

Ticker impact

Market effects

Counterpoint

Key entities

Full insider trading history

Related articles

RARE Stock Jumps 13% — Extends Gains After-Hours As FDA Clears First Sanfilippo Gene Therapy

RARE Looks 68.1% Undervalued on GF Value™ After FDA Approval Boo

Ultragenyx Pharmaceutical Inc. (RARE): Other Events

A fatal childhood disease gets its first FDA-approved treatment

Ultragenyx stock surges 10% on FDA approval for gene therapy

Ultragenyx gets FDA approval for rare disease gene therapy